Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

56%

5 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 4

2(25.0%)

Phase 2

2(25.0%)

N/A

1(12.5%)

8Total

Phase 3(3)

Phase 4(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06590012Phase 2Recruiting

Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases

Role: lead

NCT05803759Phase 4Unknown

The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment

Role: lead

NCT05813171Phase 4Unknown

The Effects of Allicor on Patients After Revascularization Treatment During a Year

Role: lead

NCT03877523Not ApplicableCompleted

Cocarnit Effects on Macrophages Polarization

Role: lead

NCT02126280Completed

Monocyte Activation in Preclinical Atherosclerosis

Role: lead

NCT01741974Phase 3Completed

Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women

Role: lead

NCT01743404Phase 2Unknown

Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis

Role: lead

NCT01742000Phase 3Completed

Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women

Role: lead

NCT01734707Phase 3Completed

Atherosclerosis Monitoring and Atherogenicity Reduction Study

Role: lead

All 9 trials loaded